Calcipotriol. A new topical antipsoriatic
- PMID: 8435908
Calcipotriol. A new topical antipsoriatic
Abstract
Calcipotriol is a synthetic vitamin D analogue. In vitro it can regulate cell differentiation and proliferation and suppress lymphocyte activities. These actions of calcipotriol at the cellular level are very similar to those of the natural hormone 1,25-(OH)2-D3. In contrast, the systemic effects on calcium and bone metabolism are at least 100 to 200 times less than those of 1,25-(OH)2-D3. Because of this unique pharmacologic profile, calcipotriol has been evaluated for the topical treatment of psoriasis. In well-designed and properly conducted studies involving more than 3000 patients, calcipotriol ointment, 50 micrograms/g, has been shown to be effective and safe for the short- and long-term treatment of psoriasis vulgaris. Calcipotriol ointment should be applied twice daily in amounts up to 100 g/week (Table 1). Used according to these guidelines, calcipotriol treatment does not affect calcium or bone metabolism. Calcipotriol is indicated for the treatment of plaque-type psoriasis vulgaris and has already been approved in several countries. It should be considered a first-line drug for the topical treatment of psoriasis.
Similar articles
-
Calcitriol ointment and clobetasol propionate cream: a new regimen for the treatment of plaque psoriasis.Eur J Dermatol. 2003 May-Jun;13(3):261-5. Eur J Dermatol. 2003. PMID: 12804986 Clinical Trial.
-
An investigator-masked comparison of the efficacy and safety of twice daily applications of calcitriol 3 microg/g ointment vs. calcipotriol 50 microg/g ointment in subjects with mild to moderate chronic plaque-type psoriasis.J Eur Acad Dermatol Venereol. 2007 Apr;21(4):466-72. doi: 10.1111/j.1468-3083.2006.01913.x. J Eur Acad Dermatol Venereol. 2007. PMID: 17373972 Clinical Trial.
-
A comparison of twice-daily calcipotriol ointment with once-daily short-contact dithranol cream therapy: a randomized controlled trial of supervised treatment of psoriasis vulgaris in a day-care setting.Br J Dermatol. 2006 Oct;155(4):800-7. doi: 10.1111/j.1365-2133.2006.07393.x. Br J Dermatol. 2006. PMID: 16965431 Clinical Trial.
-
Calcipotriol ointment. A review of its use in the management of psoriasis.Am J Clin Dermatol. 2001;2(2):95-120. doi: 10.2165/00128071-200102020-00008. Am J Clin Dermatol. 2001. PMID: 11705309 Review.
-
Management of psoriasis with calcipotriol used as monotherapy.J Am Acad Dermatol. 1997 Sep;37(3 Pt 2):S53-4. J Am Acad Dermatol. 1997. PMID: 9344185 Review.
Cited by
-
Topical vitamin D3 and low-calcemic analogs induce thymic stromal lymphopoietin in mouse keratinocytes and trigger an atopic dermatitis.Proc Natl Acad Sci U S A. 2006 Aug 1;103(31):11736-41. doi: 10.1073/pnas.0604575103. Epub 2006 Jul 31. Proc Natl Acad Sci U S A. 2006. PMID: 16880407 Free PMC article.
-
Skin chronological aging drives age-related bone loss via secretion of cystatin-A.Nat Aging. 2022 Oct;2(10):906-922. doi: 10.1038/s43587-022-00285-x. Epub 2022 Oct 6. Nat Aging. 2022. PMID: 37118283
-
Topical treatments for scalp psoriasis.Cochrane Database Syst Rev. 2016 Feb 26;2(2):CD009687. doi: 10.1002/14651858.CD009687.pub2. Cochrane Database Syst Rev. 2016. PMID: 26915340 Free PMC article.
-
A Novel Aerosol Foam Formulation of Calcipotriol and Betamethasone Has No Impact on HPA Axis and Calcium Homeostasis in Patients With Extensive Psoriasis Vulgaris.J Cutan Med Surg. 2016 Jan;20(1):44-51. doi: 10.1177/1203475415597094. Epub 2015 Jul 29. J Cutan Med Surg. 2016. PMID: 26224733 Free PMC article.
-
Superior efficacy of calcipotriene and betamethasone dipropionate aerosol foam versus ointment in patients with psoriasis vulgaris--A randomized phase II study.J Dermatolog Treat. 2016;27(2):120-7. doi: 10.3109/09546634.2015.1083935. Epub 2015 Oct 7. J Dermatolog Treat. 2016. PMID: 26444907 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical